SCHEMBL4635237

SCHEMBL4635237

N#Cc1cc(F)ccc1N1CC2C(N)C2C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 8/20 0.47
DPP8 Q6V1X1 1/20 0.47
DPP9 Q86TI2 1/20 0.47
TLR8 Q9NR97 1/20 0.39
ALDH1A1 P00352 3/20 0.37
GAA P10253 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
EPHA2 P29317 1/20 0.37
FLT4 P35916 1/20 0.37
GSK3B P49841 1/20 0.37
RARB P10826 1/20 0.37
TBXAS1 P24557 1/20 0.37
SLC6A3 Q01959 1/20 0.37
CHRM4 P08173 1/20 0.37
FFAR4 Q5NUL3 1/20 0.34
KDM4E B2RXH2 3/20 0.34
HTT P42858 3/20 0.34
LMNA P02545 2/20 0.34
TBK1 Q9UHD2 1/20 0.34
P2RX7 Q99572 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4635419 0.81 DPP4 (0.49) DPP4DPP8DPP9TLR8ALDH1A1
SCHEMBL4470692 0.80 EPHA2 (0.47) DPP4DPP9ALDH1A1GAAEPHA2
SCHEMBL3965681 0.80 EPHA2 (0.47) DPP4DPP9ALDH1A1GAAEPHA2
SCHEMBL12835672 0.80 DPP4 (0.45) DPP4DPP8DPP9TLR8CHRM4
SCHEMBL1514474 0.80 DPP4 (0.45) DPP4DPP8DPP9TLR8CHRM4
Hydrochloric Acid SCHEMBL1514448 0.79 DPP4 (0.44) DPP4DPP8DPP9TLR8CHRM4
SCHEMBL21360337 0.78 CHRM4 (0.43) DPP4ALDH1A1GAACHRM4FFAR4
SCHEMBL4635321 0.77 AR (0.60) DPP4
SCHEMBL4635925 0.77 DPP4 (0.47) DPP4DPP8DPP9CHRM4
Hydrochloric Acid SCHEMBL20141131 0.77 HTT (0.43) DPP4ALDH1A1GAACHRM4FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors RANBAXY LABORATORIES LIMITED (IN) 2008-12-04 US disclosed
EP-1931633-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS Ranbaxy Laboratories Limited (IN) 2008-06-18 EP disclosed
WO-2007029086-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors DPP4, DPP3, DPP8 DPP4 1/4885DPP8 3/4885DPP9 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.